PMID- 32390277 OWN - NLM STAT- MEDLINE DCOM- 20210618 LR - 20221005 IS - 1549-490X (Electronic) IS - 1083-7159 (Print) IS - 1083-7159 (Linking) VI - 25 IP - 10 DP - 2020 Oct TI - Efficacy of Moxifloxacin plus Treatment of Physician's Choice in Patients with Metastatic Breast Cancer. PG - e1439-e1445 LID - 10.1634/theoncologist.2020-0364 [doi] AB - LESSONS LEARNED: Moxifloxacin plus continuation of the previous treatment of physician's choice shows promising efficacy in patients with metastatic breast cancer. The addition of moxifloxacin shows well-tolerated toxicities. BACKGROUND: Recent studies have confirmed bacterial infection as an important contributor in cancer. Elimination of tumor-associated microbes may lead to a reduction in tumors and improved survival. Moxifloxacin is an orally administrated fourth-generation quinolone with broad-spectrum coverage against tumor-associated bacteria. METHODS: In this study, we assessed the efficacy and safety of moxifloxacin in combination with treatment of physician's choice (TPC) in patients with metastatic breast cancer (MBC). In this single-arm, phase II study, we recruited 30 patients with MBC who had a trend toward disease progression (stable disease [SD] with increased tumor size) during TPC before enrollment at Sun Yat-sen University Cancer Center between January 1 and July 30, 2018. Eligible patients were given moxifloxacin once daily at a dose of 400 mg from days 1 to 7 of a 28-day cycle, in addition to continuing to receive the therapy previously selected by their physicians. Tumor response was determined according to RECIST (version 1.1). Progression-free survival (PFS) was calculated using the Kaplan-Meier method. RESULTS: The concomitant use of moxifloxacin and previous TPC yielded a median PFS of 6.6 months (95% confidence interval [CI]: 4.0-9.1) and a 1-year PFS of 25.9% (95% CI: 10.0%-41.9%). Objective responses were achieved in seven (23.3%, 95% CI: 7.3%-39.4%) patients. The clinical benefit rate was 46.7% (95% CI: 27.7%-65.6%). No grade 4 adverse events (AEs) and four grade 3 AEs were observed, none of which were considered to have definite relation to moxifloxacin. CONCLUSION: The combination of moxifloxacin with previous TPC shows promising efficacy and well-tolerated toxicities in patients with MBC. CI - (c) AlphaMed Press; the data published online to support this summary are the property of the authors. FAU - Wang, Xinyue AU - Wang X AD - Department of Medical Oncology, Sun Yat-sen University Cancer Center; State Key Laboratory of Oncology in South China and Collaborative Innovation Center for Cancer Medicine, Guangzhou, People's Republic of China. FAU - Li, JiBin AU - Li J AD - Department of Clinical Research, Sun Yat-sen University Cancer Center; State Key Laboratory of Oncology in South China and Collaborative Innovation Center for Cancer Medicine, Guangzhou, People's Republic of China. FAU - Shi, Wei AU - Shi W AD - Department of Medical Oncology, Sun Yat-sen University Cancer Center; State Key Laboratory of Oncology in South China and Collaborative Innovation Center for Cancer Medicine, Guangzhou, People's Republic of China. FAU - Huang, Zhangzan AU - Huang Z AD - Department of Medical Oncology, Sun Yat-sen University Cancer Center; State Key Laboratory of Oncology in South China and Collaborative Innovation Center for Cancer Medicine, Guangzhou, People's Republic of China. FAU - Xia, Wen AU - Xia W AD - Department of Medical Oncology, Sun Yat-sen University Cancer Center; State Key Laboratory of Oncology in South China and Collaborative Innovation Center for Cancer Medicine, Guangzhou, People's Republic of China. FAU - Huang, Jiajia AU - Huang J AD - Department of Medical Oncology, Sun Yat-sen University Cancer Center; State Key Laboratory of Oncology in South China and Collaborative Innovation Center for Cancer Medicine, Guangzhou, People's Republic of China. FAU - Su, Yanhong AU - Su Y AD - Department of Medical Oncology, Sun Yat-sen University Cancer Center; State Key Laboratory of Oncology in South China and Collaborative Innovation Center for Cancer Medicine, Guangzhou, People's Republic of China. FAU - Wang, Shusen AU - Wang S AD - Department of Medical Oncology, Sun Yat-sen University Cancer Center; State Key Laboratory of Oncology in South China and Collaborative Innovation Center for Cancer Medicine, Guangzhou, People's Republic of China. FAU - Shi, Yanxia AU - Shi Y AD - Department of Medical Oncology, Sun Yat-sen University Cancer Center; State Key Laboratory of Oncology in South China and Collaborative Innovation Center for Cancer Medicine, Guangzhou, People's Republic of China. FAU - Bi, Xiwen AU - Bi X AD - Department of Medical Oncology, Sun Yat-sen University Cancer Center; State Key Laboratory of Oncology in South China and Collaborative Innovation Center for Cancer Medicine, Guangzhou, People's Republic of China. FAU - Yuan, Zhongyu AU - Yuan Z AD - Department of Medical Oncology, Sun Yat-sen University Cancer Center; State Key Laboratory of Oncology in South China and Collaborative Innovation Center for Cancer Medicine, Guangzhou, People's Republic of China. LA - eng SI - ClinicalTrials.gov/NCT03405168 PT - Clinical Trial, Phase II PT - Journal Article DEP - 20200601 PL - England TA - Oncologist JT - The oncologist JID - 9607837 RN - EC 2.7.10.1 (Receptor, ErbB-2) RN - P188ANX8CK (Trastuzumab) RN - U188XYD42P (Moxifloxacin) SB - IM MH - Antineoplastic Combined Chemotherapy Protocols/adverse effects MH - *Breast Neoplasms/drug therapy MH - Disease-Free Survival MH - Female MH - Humans MH - Moxifloxacin/therapeutic use MH - *Physicians MH - Receptor, ErbB-2/therapeutic use MH - Trastuzumab/therapeutic use MH - Treatment Outcome PMC - PMC7543292 EDAT- 2020/05/12 06:00 MHDA- 2021/06/22 06:00 PMCR- 2020/10/01 CRDT- 2020/05/12 06:00 PHST- 2019/12/02 00:00 [received] PHST- 2020/04/27 00:00 [accepted] PHST- 2020/05/12 06:00 [pubmed] PHST- 2021/06/22 06:00 [medline] PHST- 2020/05/12 06:00 [entrez] PHST- 2020/10/01 00:00 [pmc-release] AID - ONCO13357 [pii] AID - 10.1634/theoncologist.2020-0364 [doi] PST - ppublish SO - Oncologist. 2020 Oct;25(10):e1439-e1445. doi: 10.1634/theoncologist.2020-0364. Epub 2020 Jun 1.